Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

grochem australia pty ltd - sulphur - present as powdered sulphur - dust - sulphur - present as powdered sulphur active 930.0 g/kg - mixed function pesticide - citrus | grape | marrow | pawpaw | pumpkin | grapefruit | grapevine | lemon | lime | mandarin | orange | papaya | vineyard - citrus rust mite or maori mite | powdery mildew

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

grochem australia pty ltd - copper present as cuprous oxide - water dispersible granule - copper present as cuprous oxide mineral-copper active 500.0 g/kg - fungicide - almond | apple | apricot | avocado | banana | banana plantation | bean | brassica vegetables | capsicum or pepper | carrot | cel - angular leaf spot on cucurbit | anthracnose - colletotrichum spp. | anthracnose - marssonina panattoniana | anthracnose on pawpaw, mango or avocado | ascochyta blight | bacterial black spot | bacterial blight | bacterial brown spot | bacterial canker | bacterial canker on tomato | bacterial gummosis | bacterial leaf spot - x. campestris | bacterial leaf spot on lettuce | bacterial soft rot | bacterial speck | bacterial spot | bacterial spot on capsicum | black rot on cole crop/brassica | black spot - guignardia citricarpa | black spot on apples | black spot on pears | brown rot - phytophthora citrophthora | brown spot on mandarin | cercospora leaf spot - banana | chocolate spot on bean | citrus melanose | common blight | crown rot | downy mildew | downy mildew - peronospora parasitica | downy mildew on allium (onion, garlic) | downy mildew on lettuce | early blight (target spot) | freckle | grey mould - botrytis digitatum | halo blight | husk spot - cercoseptoria spp. | late or irish blight on tomato or potat

Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

grochem australia pty ltd - ziram - water dispersible granule - ziram carbamate-dithiocarbamate active 760.0 g/kg - fungicide

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - sulfamethoxazole,trimethoprim -

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - bevacizumab, quantity: 400 mg - injection, concentrated - excipient ingredients: water for injections; monobasic sodium phosphate monohydrate; trehalose dihydrate; polysorbate 20; dibasic sodium phosphate heptahydrate - ? metastatic colorectai cancer avastin (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer. ? locally recurrent or metastatic breast cancer avastin (bevacizumab) in combination with paclitaxel is indicated for the first-line treatment of metastatic breast cancer in patients in whom an anthracycline-based therapy is contraindicated.(see clinical trials). ? advanced, metastatic or recurrent non-squamous non-small cell lung cancer (nsclc) avastin (bevacizumab), in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent, non-squamous non-small cell lung cancer. ? advanced and/or metastatic renai cell cancer avastin (bevacizumab) in combination with interferon alfa-2a is indicated for treatment of patients with advanced and/or metastatic renal cell cancer ? grade iv glioma avastin (bevacizumab) as a single agent, is indicated for t

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - bevacizumab, quantity: 100 mg - injection, concentrated - excipient ingredients: monobasic sodium phosphate monohydrate; water for injections; polysorbate 20; trehalose dihydrate; dibasic sodium phosphate heptahydrate - ? metastatic colorectai cancer avastin (bevacizumab) in combination with fluoropyrimidine-based chemotherapy is indicated for the treatment of patients with metastatic colorectal cancer. ? locally recurrent or metastatic breast cancer avastin (bevacizumab) in combination with paclitaxel is indicated for the first-line treatment of metastatic breast cancer in patients in whom an anthracycline-based therapy is contraindicated.(see clinical trials). ? advanced, metastatic or recurrent non-squamous non-small cell lung cancer (nsclc) avastin (bevacizumab), in combination with carboplatin and paclitaxel, is indicated for first-line treatment of patients with unresectable advanced, metastatic or recurrent, non-squamous non-small cell lung cancer. ? advanced and/or metastatic renai cell cancer avastin (bevacizumab) in combination with interferon alfa-2a is indicated for treatment of patients with advanced and/or metastatic renal cell cancer ? grade iv glioma avastin (bevacizumab) as a single agent, is indicated for t

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - atezolizumab, quantity: 1200 mg - injection, concentrated - excipient ingredients: histidine; sucrose; water for injections; polysorbate 20; glacial acetic acid - early-stage non-small cell lung cancer,tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adult patients with stage ii to iiia (as per 7th edition of the uicc/ajcc staging system) nsclc whose tumours have pd-l1 expression on greater than or equal to 50% of tumour cells.,metastatic non-small cell lung cancer,tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.,tecentriq, in combination with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and carboplatin, is indicated for first-line treatment of patients with metastatic non-squamous nsclc who do not have tumour egfr or alk genomic aberrations.,tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic nsclc after prior chemotherapy. patients with egfr mutant or alk-positive nsclc should also have received targeted therapies before receiving tecentriq.,small cell lung cancer,tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (es-sclc).,urothelial carcinoma,tecentriq is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who,? are considered cisplatin ineligible and whose tumours express pd-l1 (pd-l1 stained tumour-infiltrating immune cells [ic] covering greater than or equal to 5% of the tumour area), as determined by a validated test, or,? are considered ineligible for any other platinum-containing chemotherapy regardless of the level of tumour pd-l1 expression.,this indication is approved based on overall response rate and duration of response in a single-arm study. improvements in overall survival, progression-free survival, or health-related quality of life have not been established.,hepatocellular carcinoma,tecentriq, in combination with bevacizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (hcc) who have not received prior systemic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - dornase alfa, quantity: 1 mg/ml - spray, solution - excipient ingredients: water for injections; calcium chloride dihydrate; sodium chloride - chronic administration of pulmozyme is indicated for the management of demonstrated respiratory complications in cystic fibrosis. continued use should depend on demonstrating a sustained benefit based on clinical response and, if able to be performed, pulmonary function tests.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - atezolizumab, quantity: 840 mg - injection, concentrated - excipient ingredients: histidine; glacial acetic acid; polysorbate 20; sucrose; water for injections - early-stage non-small cell lung cancer,tecentriq as monotherapy is indicated as adjuvant treatment following complete resection and no progression after platinum-based adjuvant chemotherapy for adult patients with stage ii to iiia (as per 7th edition of the uicc/ajcc staging system) nsclc whose tumours have pd-l1 expression on greater than or equal to 50% of tumour cells.,metastatic non-small cell lung cancer,tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated for the first-line treatment of adult patients with metastatic non-squamous non-small cell lung cancer (nsclc). in patients with egfr mutant or alk-positive nsclc, tecentriq, in combination with bevacizumab, paclitaxel and carboplatin, is indicated only after failure of appropriate targeted therapies.,tecentriq, in combination with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) and carboplatin, is indicated for first-line treatment of patients with metastatic non-squamous nsclc who do not have tumour egfr or alk genomic aberrations.,tecentriq as monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic nsclc after prior chemotherapy. patients with egfr mutant or alk-positive nsclc should also have received targeted therapies before receiving tecentriq.,small cell lung cancer,tecentriq, in combination with carboplatin and etoposide, is indicated for the first-line treatment of patients with extensive-stage small cell lung cancer (es-sclc).,urothelial carcinoma,tecentriq is indicated for the treatment of patients with locally advanced or metastatic urothelial carcinoma who,? are considered cisplatin ineligible and whose tumours express pd-l1 (pd-l1 stained tumour-infiltrating immune cells [ic] covering greater than or equal to 5% of the tumour area), as determined by a validated test, or,? are considered ineligible for any other platinum-containing chemotherapy regardless of the level of tumour pd-l1 expression.,this indication is approved based on overall response rate and duration of response in a single-arm study. improvements in overall survival, progression-free survival, or health-related quality of life have not been established.,hepatocellular carcinoma,tecentriq, in combination with bevacizumab, is indicated for the treatment of patients with unresectable or metastatic hepatocellular carcinoma (hcc) who have not received prior systemic therapy.

Australia - English - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - clonazepam -